Paranta Biosciences Limited

Paranta Biosciences is an early stage drug development company committed to the research, development and commercialization of recombinant human follistatin for the treatment of respiratory diseases and conditions. The company commenced operations as a private company in September 2010 and became an unlisted public company in April 2011. Paranta Biosciences is based in Melbourne, Australia.